USD
$0.00
(0.00%
)At Close (As of Sep 8, 2025)
$333.61M
Market Cap
-
P/E Ratio
-1.18
EPS
$11.16
52 Week High
$2.90
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $20K |
Total Revenue | $20K |
Cost Of Revenue | $238K |
Costof Goods And Services Sold | $238K |
Operating Income | -$103M |
Selling General And Administrative | $21M |
Research And Development | $82M |
Operating Expenses | $103M |
Investment Income Net | - |
Net Interest Income | $8.1M |
Interest Income | $8.1M |
Interest Expense | $9K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $238K |
Income Before Tax | -$95M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$95M |
Comprehensive Income Net Of Tax | - |
Ebit | -$95M |
Ebitda | -$95M |
Net Income | -$95M |
Field | Value (USD) |
---|---|
Total Assets | $139M |
Total Current Assets | $137M |
Cash And Cash Equivalents At Carrying Value | $37M |
Cash And Short Term Investments | $37M |
Inventory | - |
Current Net Receivables | $3.1M |
Total Non Current Assets | $2.1M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $95M |
Other Current Assets | $2.2M |
Other Non Current Assets | - |
Total Liabilities | $16M |
Total Current Liabilities | $10M |
Current Accounts Payable | $211K |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $558K |
Total Non Current Liabilities | $5.3M |
Capital Lease Obligations | $1.7M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $1.7M |
Other Current Liabilities | $9.7M |
Other Non Current Liabilities | $3.9M |
Total Shareholder Equity | $124M |
Treasury Stock | - |
Retained Earnings | -$561M |
Common Stock | $7K |
Common Stock Shares Outstanding | $71M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$80M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $238K |
Capital Expenditures | $0 |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$28M |
Cashflow From Financing | $10M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | $300K |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$95M |
Field | Value (USD) |
---|---|
Gross Profit | $20K |
Total Revenue | $20K |
Cost Of Revenue | $238K |
Costof Goods And Services Sold | $238K |
Operating Income | -$103M |
Selling General And Administrative | $21M |
Research And Development | $82M |
Operating Expenses | $103M |
Investment Income Net | - |
Net Interest Income | $8.1M |
Interest Income | $8.1M |
Interest Expense | $9K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $238K |
Income Before Tax | -$95M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$95M |
Comprehensive Income Net Of Tax | - |
Ebit | -$95M |
Ebitda | -$95M |
Net Income | -$95M |
Field | Value |
---|---|
Ex Dividend Date | 2017-02-06 |
Declaration Date | None |
Record Date | None |
Payment Date | None |
Amount | 2.91 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.